Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Lowered to $45.00 at Chardan Capital
Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) had its price objective decreased by Chardan Capital from $54.00 to $45.00 in a research note issued to investors on Friday,Benzinga reports. Chardan Capital currently has a buy rating on the biotechnology company’s stock. Several other equities analysts also recently commented on the company. BMO Capital Markets assumed coverage […]
Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) had its price objective decreased by Chardan Capital from $54.00 to $45.00 in a research note issued to investors on Friday,Benzinga reports. Chardan Capital currently has a buy rating on the biotechnology company’s stock. Several other equities analysts also recently commented on the company. BMO Capital Markets assumed coverage […]
